

Kinetics and Mechanism of Protein Tyrosine Phosphatase 1B Inactivation by Acrolein

Derrick R. Seiner, Jason N. LaButti, and Kent S. Gates*

Departments of Chemistry and Biochemistry, University of Missouri, Columbia, Missouri 65211

Received June 11, 2007

Human cells are exposed to the electrophilic α,β -unsaturated aldehyde acrolein from a variety of sources. The reaction of acrolein with functionally critical protein thiol residues can yield important biological consequences. Protein tyrosine phosphatases (PTPs) are an important class of cysteine-dependent enzymes whose reactivity with acrolein previously has not been well-characterized. These enzymes catalyze the dephosphorylation of phosphotyrosine residues on proteins via a phosphocysteine intermediate. PTPs work in tandem with protein tyrosine kinases to regulate a number of critically important mammalian signal transduction pathways. We find that acrolein is a potent time-dependent inactivator of the enzyme PTP1B ($k_{\text{inact}} = 0.02 \pm 0.005 \text{ s}^{-1}$ and $K_I = 2.3 \pm 0.6 \times 10^{-4} \text{ M}$). The enzyme activity does not return upon gel filtration of the inactivated enzyme, and addition of the competitive phosphatase inhibitor vanadate slows inactivation of PTP1B by acrolein. Together, these observations suggest that acrolein covalently modifies the active site of PTP1B. Mass spectrometric analysis reveals that acrolein modifies the catalytic cysteine residue at the active site of the enzyme. Aliphatic aldehydes such as glyoxal, acetaldehyde, and propanal are relatively weak inactivators of PTP1B under the conditions employed here. Similarly, unsaturated aldehydes such as crotonaldehyde and 3-methyl-2-butenal bearing substitution at the alkene terminus are poor inactivators of the enzyme. Overall, the data suggest that enzyme inactivation occurs via conjugate addition of the catalytic cysteine residue to the carbon–carbon double bond of acrolein. The results indicate that inactivation of PTPs should be considered as a possible contributor to the diverse biological activities of acrolein and structurally related α,β -unsaturated aldehydes.

Introduction

Human cells are exposed to the electrophilic α,β -unsaturated aldehyde acrolein from a variety of sources (1, 2). Acrolein can be generated in the cell by endogenous lipid peroxidation (3–5) and oxidation of amino acids (6) or introduced via dietary sources (1), cigarette smoke (7), and the metabolism of drugs (8–11) or other xenobiotics (12, 13). Acrolein displays a wide range of biological activities (1, 2). One important chemical reaction underlying the biological action of acrolein involves covalent modification of cysteine thiol residues on proteins. Specifically, reactions of acrolein with proteins that contain functionally critical thiol side chains such as cysteine proteases (caspase-3) (14–16), some ion channels (TRPA1) (17), and some transcription factors (NF- κ B, Keap1/Nrf2) (18, 19) have the potential to yield significant biological effects.

Protein tyrosine phosphatases (PTPs) are an important class of cysteine-dependent enzymes whose reactivity with acrolein has not been well-characterized. These enzymes catalyze the dephosphorylation of phosphotyrosine residues on proteins via a phosphocysteine intermediate as shown in Scheme 1 (20–25). PTPs work in tandem with protein tyrosine kinases to regulate a number of critically important mammalian signal transduction pathways (20–26). Not surprisingly, inhibition or inactivation of PTPs has the potential to yield profound biological consequences (27–32).

In the work reported here, we examined the kinetics and mechanism of PTP inactivation by acrolein. We find that acrolein is a potent irreversible inactivator of the enzyme

PTP1B. The data further suggest that the inactivation reaction occurs via conjugate addition of the active site cysteine-215 to the carbon–carbon double bond of acrolein.


Materials and Methods

Chemicals and Reagents. Reagents were purchased from the following suppliers: buffer salts, *p*-nitrophenyl phosphate (pNPP), thiols, trifluoroacetic acid (TFA), sodium orthovanadate, acetaldehyde, 3-methyl-2-butenal, and crotonaldehyde were obtained from Sigma-Aldrich (St. Louis, MO). Catalase (catalog no. 106810) and SOD (catalog no. 837113) were obtained from Roche Bioscience (Palo Alto, CA). Acrolein and glyoxal were obtained from Acros Organics. Sequencing grade modified trypsin (catalog no. V5111) was obtained from Promega. Ammonium bicarbonate was obtained from Fisher Scientific. Recombinant PTP1B (a.a. 1–322) was prepared in our laboratory as reported previously (33). The concentration of active PTP1B in the samples was determined as described previously (33).

Time-Dependent Inactivation of PTP1B. Inactivation assays were performed using modifications of existing literature protocols (34–36). Free thiols were removed from a stock solution of purified PTP1B using Zeba mini centrifugal buffer exchange columns (Pierce, catalog no. 89882) according to the manufacturer's protocol. The exchange buffer contained 100 mM TRIS-HCl, 10 mM DTPA, and 0.05% NP-40, pH 7.4. In the inactivation reactions, acrolein was added as a stock solution in water to a mixture containing PTP1B in Tris-HCl (100 mM), DTPA (10 mM), and NP-40 (0.05% v/v) at 30 °C (final concentrations: acrolein, 20–60 μM ; Tris-HCl, 50 mM; DTPA, 5 mM; NP-40, 0.025% v/v; and PTP1B, 75 nM). Aliquots (10 μL) were removed at various time points (1, 2, and 5 min) and placed in 490 μL of PTP1B assay buffer consisting of bis-Tris (50 mM, pH 6.0), NaCl (100 mM), DTPA (10 mM), and pNPP (20 mM) at 30 °C for 10 min. The enzymatic reaction was quenched by addition of NaOH (500 μL of a 2 N solution in water),

* To whom correspondence should be addressed. Tel: 1-573-882-6763. Fax: 1-573-882-2754. E-mail: gatesk@missouri.edu.

Scheme 1



and the amount of *p*-nitrophenol released during the assay was determined at 25 °C by measuring the absorbance at 410 nm using a UV-vis spectrometer.

Gel Filtration of Acrolein-Inactivated PTP1B. A solution of acrolein in water (10 μ L of 5 mM) was added to PTP1B [40 μ L of a 4 μ M solution in Tris-HCl (100 mM), DTPA (10 mM), and NP-40 (0.05% v/v)]. After 10 min, an aliquot (10 μ L) was removed and tested for activity to confirm that the enzyme was completely inactivated. An aliquot of the remaining solution (12 μ L) was gel filtered through a Zeba micro spin column according to the manufacturer's protocol. The exchange buffer contained 100 mM Tris-HCl, 10 mM NaCl, 10 mM DTPA, and 0.05% NP-40, pH 7.4. Following buffer exchange, a 10 μ L aliquot was tested for PTP1B activity as described above. No measurable return of PTP1B activity was observed vs a control sample treated in an identical manner except without inactivation by acrolein.

Time-Dependent Inactivation in the Presence of a Competitive PTP1B Inhibitor or Superoxide Dismutase or Catalase. An aliquot of thiol-free enzyme [20 μ L of a 4 μ M solution in Tris-HCl (100 mM), DTPA (10 mM), and NP-40 (0.05% v/v)] was combined with an aqueous solution of acrolein and orthovanadate (20 μ L of a mixture containing 500 μ M acrolein and 1 mM orthovanadate in water) at 25 °C (final concentrations: PTP1B, 2 μ M; acrolein, 250 μ M; orthovanadate, 500 μ M; Tris-HCl, 50 mM; DTPA, 5 mM; and NP-40, 0.025% v/v). After 5 min, a 10 μ L aliquot was removed and added to a cuvette containing a three-component PTP1B assay buffer (990 μ L) consisting of sodium acetate (100 mM), bis-Tris (50 mM), Tris (50 mM), and pNPP (10 mM), at pH 7.0 (final volume of 1 mL). Immediately following the addition of enzyme to the cuvette, the assay was mixed by repeated inversion, and the enzyme catalyzed the release of *p*-nitrophenol monitored at 25 °C by measuring the increase in absorbance at 410 nm. Data points were taken every 2 s. In the assays designed to probe the potential role of reactive oxygen species in this inactivation process, acrolein (10 μ L of a 100 mM stock solution) was added to a cuvette containing the assay buffer (985 μ L of a mixture containing sodium acetate, 100 mM; bis-Tris, 50 mM; Tris, 50 mM; pNPP, 10 mM, and either SOD, 10 μ g/mL, or catalase, 0.5 μ g/mL, at pH 7.0), followed by thiol-free PTP1B (5 μ L of a 4 μ M solution in Tris-HCl, 100 mM; DTPA, 10 mM; and NP-40, 0.05% v/v). The PTP1B activity was then monitored as described above. The presence of catalase or superoxide dismutase exerted no measurable effect on the inactivation reaction.

Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI TOF)/TOF MS and Nanospray MS/MS Analysis of Acrolein-Modified PTP1B. A solution of acrolein (5 μ L, 18 mM in water) was added to a solution containing thiol-free PTP1B (45 μ L of an approximately 14 pmol/ μ L solution in Tris-HCl, 100 mM; NaCl, 10 mM; DTPA, 10 mM; and NP-40, 0.05%; at pH 7.4), and the resulting mixture was incubated for 30 min at 25 °C. A control sample containing no acrolein was also prepared. After incubation, both solutions were passed through a Zeba mini centrifugal buffer exchange column. To the resulting mixtures, sequence grade modified trypsin (50 μ L of a 1 μ g/50 μ L solution in 50 mM ammonium bicarbonate) was added. The digestion was

incubated at 37 °C for 18 h and then quenched with TFA (5 μ L of a 10% aqueous solution). An aliquot (20 μ L) of each solution was transferred to a microcentrifuge tube, frozen in liquid nitrogen, and lyophilized to dryness. The residue was resuspended in water (10 μ L) and again lyophilized. The final dried sample was reconstituted in acetonitrile/water/88% formic acid (5 μ L of 700/290/10 v/v/v). For MALDI TOF/TOF MS analysis, a 0.6 μ L portion of diluted sample was mixed with an equal volume of α -cyano-4-hydroxycinnamic acid (CHCA) matrix solution [5 mg CHCA/mL in 500/455/20/25 (v/v/v/v) acetonitrile/water/10% TFA/400 mM aqueous ammonium dihydrogen phosphate]. Aliquots (0.4 μ L) of the mixture were deposited on a polished stainless steel target. Crystallization of the mixture proceeded under ambient conditions. Mass spectra were acquired on an Applied Biosystems Inc. 4700 MALDI TOF/TOF mass spectrometer with a 355 nm Nd:YAG laser (200 Hz) in the positive ion-delayed extraction reflector MS mode. The MS spectra (2000 laser shots summed/averaged) were acquired over the mass range 700–4000 Da. Each MS spectrum was recalibrated internally using the masses (monoisotopic $[M + H]^+$) for the PTP1B tryptic fragments observed at 1366.675 Da ([13–24]) and 2508.288 Da ([293–314]). For nanospray MS/MS of the active site peptide 200–221, ZipTip (Millipore, standard C18) cleanup of sample with fractions of 50/940/10, 100/890/10, and 200/790/10 (v/v/v) acetonitrile/water/88% formic acid (AWF) were pooled and then lyophilized to dryness. The sample was reconstituted in 4 μ L of 700/290/10 AWF for nanospray QTOF MS analysis on an Applied Biosystems/MDS Sciex (Foster City, CA) QStar/Pulsar/I instrument fitted with a Proxeon (Odense, Denmark) nanospray source. A pulsar frequency of 6.99 kHz was used for MS/MS mass range 50–2000 Da. MS/MS spectra were obtained with N_2 collision gas. The MS/MS of the 3^+ ion at 744.37 Da for the peptide of interest was obtained with a collision energy of 35 V. The instrument software was Analyst QS, and the data analysis software was BioAnalyst 1.1.

Results

Kinetics of PTP1B Inactivation by Acrolein. We utilized the catalytic subunit of human PTP1B (a.a. 1–322) as an archetypal member of the PTP family of enzymes (20–25). We find that acrolein is a potent time-dependent inactivator of PTP1B (Figure 1A). A Kitz–Wilson replot of the inactivation data (Figure 1B) reveals that the maximum rate of inactivation at saturating concentrations of acrolein, k_{inact} , is $0.02 \pm 0.005 \text{ s}^{-1}$, while the concentration of acrolein required to achieve a half-maximal rate of inactivation, K_I , is $2.3 \pm 0.6 \times 10^{-4} \text{ M}$. It is worth noting that the apparent second-order rate constant for inactivation of the enzyme by acrolein ($k_{\text{inact}}/K_I = 87 \text{ M}^{-1} \text{ s}^{-1}$) is comparable to that for hydrogen peroxide ($10 \text{ M}^{-1} \text{ s}^{-1}$) (37, 38), a known endogenous regulator of PTP1B activity (39, 40). Inactivation of PTP1B by acrolein is not reversed by gel filtration or dialysis to remove excess inactivator. This observation, along with the time-dependent nature of the reaction, indicates that the inactivation of PTP1B by acrolein




Figure 1. Semilog plot of time courses for the inactivation of PTP1B by various concentrations of acrolein (A) and Kitz-Wilson replot of the inactivation data (B).




Figure 2. Inactivation of PTP1B by acrolein is slowed by the presence of the competitive inhibitor orthovanadate.

involves covalent modification of the enzyme. The inactivation process is slowed by addition of the competitive PTP1B inhibitor ortho vanadate (35) (Figure 2), thereby providing evidence that the reaction is active site-directed.

Inactivation of PTP1B by Acrolein Does Not Involve Reactive Oxygen Species. PTPs can be inactivated by reactive oxygen species such as superoxide radical and hydrogen peroxide (33, 37, 38). These agents inactivate PTP1B via oxidation of the active site cysteine-215 to the sulfenic acid oxidation state (38, 41–43). In the context of the current study, it is important to note that spontaneous autooxidation of aldehydes in aerobic solution has the potential to generate superoxide radical and hydrogen peroxide (44). The possible involvement of reactive oxygen species in the inactivation of PTP1B by acrolein was ruled out by the observation that the presence of the superoxide- and hydrogen peroxide-destroying enzymes superoxide dismutase (SOD) and catalase (45) has no effect on the rate of the inactivation reaction (data not shown).

Mass Spectrometry of Acrolein-Inactivated PTP1B. Acrolein can covalently modify a number of amino acid residues in proteins, including histidine, lysine, and cysteine (3, 14–17, 46–50). Importantly, the active site of PTP1B contains both a cysteine (Cys-215) and a histidine (His-216) residue that are required for catalytic activity (51). Mass spectrometry was employed to shed light on the site(s) at which acrolein covalently modifies the active site of PTP1B. Toward this end, acrolein-inactivated PTP1B was subjected to tryptic digestion and the resulting fragments were analyzed by MALDI-TOF-TOF mass spectrometry. Signals for many of the expected (unmodified) tryptic fragments of PTP1B were observed in the mass spectrum. Importantly, a major signal was seen at m/z 2231.09 corresponding to the acrolein-modified active site peptide a.a.

200–221. A very weak signal was observed for the unmodified active site peptide (m/z 2175.17). In addition, weak signals were detected, consistent with acrolein modification of four other cysteine-containing tryptic fragments corresponding to a.a. 25–33 (m/z 1117.47), 80–103 (m/z 2920.38), 121–128 (m/z 1079.66), and 222–237 (m/z 1824.80). Nanospray MS/MS-TOF was employed to further characterize the site(s) of acrolein modification in the active site peptide a.a. 200–221 (m/z 2231.09 $[\text{M} + \text{H}]^+$). The masses for the b_{12} – b_{15} ions are those expected for the unmodified peptides (Figure 3). On the other hand, the masses of the b_{16} – b_{17} ions are increased by +56 Da, consistent with modification of these fragment ions by acrolein. Similarly, the masses for the y_5 and y_6 ions are consistent with those expected for the unmodified peptide fragments, while the masses for y_7 – y_{13} ions are increased by +56 Da. Overall, the data indicate that acrolein inactivates PTP1B primarily via reaction with the active site cysteine-215. Weak signals corresponding to the acrolein-modified b_{15} and unmodified y_7 ions are observed, suggesting that some modification also occurs at histidine-214 of the active site peptide.

Structure-Activity Studies with Related Aldehydes Suggest That Acrolein Inactivates PTP1B via a Conjugate Addition Mechanism. In aqueous solution, simple thiols react with acrolein via initial conjugate addition to the double bond of the α,β -unsaturated aldehyde, rather than by addition to the aldehyde moiety (52). Thus, we anticipated that the inactivation of PTP1B by acrolein may proceed via the conjugate addition mechanism shown in Scheme 2. Consistent with this expectation, we find that aliphatic aldehydes such as glyoxal, acetaldehyde, and propanal, lacking the unsaturation found in acrolein, are relatively poor inactivators of the enzyme (Table 1). These results are in line with previous work showing that simple aldehydes such as acetaldehyde do not effectively inactivate PTP1B (53). It is worth noting that more functionalized peptidyl aldehydes that capture noncovalent binding interactions with the enzyme active site are slow-binding, reversible covalent inhibitors of protein tyrosine phosphatases (54, 55). Also consistent with our favored conjugate addition mechanism for the inactivation of PTP1B by acrolein, we find that analogues such as crotonaldehyde and 3-methyl-2-butenal, possessing steric bulk at the terminal position of the double bond, are relatively weak inactivators of the enzyme (Table 1).

Discussion

Acrolein has previously been shown to inactivate a variety of enzymes including DNA methyltransferase (46), protein disulfide isomerase (49), glutathione reductase (47), caspase-3 (14–16), and carbonic anhydrase (48). In addition, modification of ion channels (17) and transcription factors (18, 19) by acrolein





Figure 3. ESI⁺-MS/MS analysis of the acrolein-modified PTP1B active site tryptic fragment, E²⁰⁰SGSLSP^{EH}GPPVVHCSAGIGR²²¹. Cysteine 215 is the active site nucleophile of PTP1B. Acrolein-modified fragment ions are denoted by an asterisk.



can alter their functional properties. Here, we provide evidence that acrolein is a potent irreversible inactivator of the enzyme PTP1B ($k_{\text{inact}} = 0.02 \pm 0.005 \text{ s}^{-1}$, $K_I = 2.3 \pm 0.6 \times 10^{-4} \text{ M}$). The apparent second-order rate constant for the inactivation of PTP1B by acrolein ($87 \text{ M}^{-1} \text{ s}^{-1}$) is comparable to that reported previously for hydrogen peroxide ($10 \text{ M}^{-1} \text{ s}^{-1}$), a known endogenous regulator of the enzyme (37–40). In general, our findings mesh with previous reports that acrolein and structurally related lipid peroxidation products inhibit PTP activity although, in the earlier work, neither the kinetics nor the mechanism of PTP inhibition by acrolein were elucidated (53, 56, 57). In our study, mass spectrometry of the inactivated enzyme indicates that the active site cysteine-215 residue is modified by acrolein. Examination of a series of structurally related aldehydes further shows that the double bond found in acrolein is central to its properties as a phosphatase inactivator. This fact is revealed by the observation that simple aliphatic aldehydes do not inactivate PTP1B under the conditions employed for these studies. Furthermore, steric bulk at the alkene terminus diminishes the PTP1B-inactivating properties of compounds in this series. Together, these observations support an inactivation

Table 1. Inactivation of PTP1B by Various Aldehydes

Compound	% Remaining Enzyme Activity ^a
Acrolein	4 ± 3%
Crotonaldehyde	85 ± 2%
Glyoxal	93 ± 2%
3-Methyl-2-butenal	95 ± 3%
Propanal	93 ± 4%
Acetaldehyde	> 95%

^a A solution containing PTP1B (225 nM) in sodium acetate (100 mM), bis-Tris (50 mM), Tris (50 mM), DETAPAC (5 mM), and DMF (5% by volume), pH 7, was incubated with various aldehydes (500 μM) at 25 °C. After 10 min, an aliquot (10 μL) was removed from the solution and the fraction of remaining enzyme activity (vs a control sample containing no aldehyde) was determined as described in the Materials and Methods.

mechanism involving conjugate addition of the active site cysteine-215 to the carbon-carbon double bond of acrolein (Scheme 2).

In conclusion, inactivation of PTPs can yield profound biological consequences arising from the disruption of cellular signaling pathways (27–32). The results reported here indicate that inactivation of PTPs can be considered as a possible contributor to the diverse biological activities (1, 2) of acrolein and structurally related α,β -unsaturated aldehydes.

Acknowledgment. We thank Beverly DaGue for mass spectrometry and the National Institutes of Health for partial support of this work (CA 83925 and CA 119131).

References

- (1) O'Brien, P. J., Siraki, A. G., and Shangari, N. (2005) Aldehyde sources, metabolism, molecular toxicity, and possible effects on human health. *Crit. Rev. Toxicol.* 35, 609–662.
- (2) Beauchamp, R. O., Jr., Andjelkovich, D. A., Kligerman, A. D., Morgan, K. T., and Heck, H. (1985) A critical review of the literature on acrolein toxicity. *Crit. Rev. Toxicol.* 14, 309–380.
- (3) Uchida, K., Kanematsu, M., Sakai, K., Matsuda, T., Hattori, N., Mizuno, Y., Suzuki, D., Miyata, T., Noguchi, N., Niki, E., and Osawa, T. (1998) Protein-bound acrolein: Potential markers for oxidative stress. *Proc. Natl. Acad. Sci. U.S.A.* 95, 4882–4887.
- (4) Montine, T. J., Neely, M. D., Quinn, J. F., Beal, M. F., Markesbery, W. R., Roberts, L. J., and Morrow, J. D. (2002) Lipid peroxidation in aging brain and Alzheimer's. *Free Radical Biol. Med.* 33, 620–626.
- (5) Arlt, S., Beisiegel, U., and Kontush, A. (2002) Lipid peroxidation in neurodegeneration: new insights into Alzheimer's disease. *Curr. Opin. Lipidol.* 13, 289–294.
- (6) Anderson, M. M., Hazen, S. L., Hsu, F. F., and Heinecke, J. W. (1997) Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein. *J. Clin. Invest.* 99, 424–432.
- (7) Hecht, S. S. (2006) Smoking and lung cancer—A new role for an old toxicant? *Proc. Natl. Acad. Sci. U.S.A.* 103, 15725–15726.
- (8) Ramu, K., Fraiser, L. H., Mamiya, B., Ahmed, T., and Kehrer, J. P. (1995) Acrolein mercapturates: synthesis, characterization, and assessment of their role in the bladder toxicity of cyclophosphamide. *Chem. Res. Toxicol.* 8, 515–524.
- (9) Patel, J. M. (1990) Metabolism and pulmonary toxicity of cyclophosphamide. *Pharmacol. Ther.* 47, 137–146.
- (10) Zhang, J., Tian, Q., and Zhou, S.-F. (2006) Clinical pharmacology of cyclophosphamide and ifosfamide. *Curr. Drug Ther.* 1, 55–84.
- (11) Kaijser, G. P., Korst, A., Beijnen, J. H., Bult, A., and Underberg, W. J. M. (1993) The analysis of ifosfamide and its metabolites (review). *Anticancer Res.* 13, 1311–1324.
- (12) Hashmi, M., Vamvakas, S., and Anders, M. W. (1992) Bioactivation mechanism of S-(3-oxopropyl)-N-acetyl-L-cysteine, the mercapturic acid of acrolein. *Chem. Res. Toxicol.* 5, 360–365.
- (13) Atzori, L., Dore, M., and Congiu, L. (1989) Aspects of allyl alcohol toxicity. *Drug Metab. Drug Interact.* 7, 295–319.
- (14) Finkelstein, E. I., Ruben, J., Koot, C. W., Hristova, M., and van der Vliet, A. (2005) Regulation of constitutive neutrophil apoptosis by the α,β -unsaturated aldehydes acrolein and 4-hydroxynonenal. *Am. J. Physiol.* 289, L1019–L1028.
- (15) Kern, J. C., and Kehrer, J. P. (2002) Acrolein-induced cell death: a caspase-influenced decision between apoptosis and oncosis/necrosis. *Chem.-Biol. Interact.* 139, 79–95.
- (16) Tanel, A., and Averill-Bates, D. A. (2005) The aldehyde acrolein induces apoptosis via activation of the mitochondrial pathway. *Biochim. Biophys. Acta* 1743 (3), 255–267.
- (17) Macpherson, L. J., Dubin, A. E., Evans, M. J., Marr, F., Schultz, P. G., Cravatt, B. F., and Patapoutian, A. (2007) Noxious compounds activate TRPA1 ion channels through covalent modification of cysteines. *Nature* 445, 541–545.
- (18) Horton, N. D., Biswal, S. S., Corrigan, L. L., Bratta, J., and Kehrer, J. P. (1999) Acrolein causes inhibitor kB-independent decreases in nuclear factor kB activation in human lung adenocarcinoma (A549) cells. *J. Biol. Chem.* 274, 9200–9206.
- (19) Tirumalai, R., Rajesh Kumar, T., Mai, K. H., and Biswal, S. (2002) Acrolein causes transcriptional induction of phase II genes by activation of Nrf2 in human lung type II epithelial (A549) cells. *Toxicol. Lett.* 132, 27–36.
- (20) Alonso, A., Sasin, J., Bottini, N., Friedberg, I., Friedberg, I., Ostermann, A., Godzik, A., Hunter, T., Dixon, J. E., and Mustelin, T. (2004) Protein tyrosine phosphatases in the human genome. *Cell* 117, 699–711.
- (21) Barford, D. (1995) Protein phosphatases. *Curr. Opin. Struct. Biol.* 5, 728–734.
- (22) Jackson, M. D., and Denu, J. M. (2001) Molecular reactions of protein phosphatases—Insights from structure and chemistry. *Chem. Rev.* 101, 2313–2340.
- (23) Neel, B. G., and Tonks, N. K. (1997) Protein tyrosine phosphatases in signal transduction. *Curr. Opin. Cell Biol.* 9, 193–204.
- (24) Stone, R. L., and Dixon, J. E. (1994) Protein-tyrosine phosphatases. *J. Biol. Chem.* 269, 31323–31326.
- (25) Zhang, Z.-Y. (2003) Chemical and mechanistic approaches to the study of protein tyrosine phosphatases. *Acc. Chem. Res.* 36, 385–392.
- (26) Hunter, T. (2000) Signaling-2000 and beyond. *Cell* 100, 113–127.
- (27) Bialy, L., and Waldmann, H. (2005) Inhibitors of protein tyrosine phosphatases: next generation drugs? *Angew. Chem. Int. Ed.* 44, 3814–3839.
- (28) Johnson, T. O., Ermoliev, J., and Jirousek, M. R. (2002) Protein tyrosine phosphatase 1B inhibitors for diabetes. *Nat. Rev. Drug Discovery* 1, 696–709.
- (29) Hoffman, B. T., Nelson, M. R., Burdick, K., and Baxter, S. M. (2004) Protein tyrosine phosphatases: strategies for distinguishing proteins in a family containing multiple drug targets and anti-targets. *Curr. Pharm. Des.* 10, 1161–1181.
- (30) Bridges, A. J. (2005) Therapeutic challenges of kinase and phosphatase inhibition and use in anti-diabetic strategy. *Biochem. Soc. Trans.* 33, 343–345.
- (31) Julien, S. G., Dubé, N., Read, M., Penney, J., Paquet, M., Han, Y., Kennedy, B. P., Muller, W. J., and Tremblay, M. L. (2007) Protein tyrosine phosphatase 1B deficiency or inhibition delays Erb2-induced mammary tumorigenesis and protects from lung metastasis. *Nat. Genet.* 39, 338–346.
- (32) Tonks, N. K., and Muthuswamy, S. K. (2007) A brake becomes an accelerator: PTP1B—A new therapeutic target for breast cancer. *Cancer Cell* 11, 214–215.
- (33) LaButti, J. N., Chowdhury, G., Reilly, T. J., and Gates, K. S. (2007) Redox regulation of protein tyrosine phosphatase 1B by peroxymonophosphate. *J. Am. Chem. Soc.* 129, 5320–5321.
- (34) Arabaci, G., Guo, X.-C., Beebe, K. D., Coggeshall, K. M., and Pei, D. (1999) α -Haloacetophenone derivatives as photoreversible covalent inhibitors of protein tyrosine phosphatases. *J. Am. Chem. Soc.* 121, 5085–5086.
- (35) Montalibet, J., Skorey, K. I., and Kennedy, B. P. (2005) Protein tyrosine phosphatase: Enzymatic assays. *Methods* 35, 2–8.
- (36) Silverman, R. B. (1988) *Mechanism-Based Enzyme Inactivation: Chemistry and Enzymology*, Vol. I. CRC Press, Boca Raton.
- (37) Barrett, W. C., DeGnore, J. P., Keng, Y.-F., Zhang, Z.-Y., Yim, M. B., and Chock, P. B. (1999) Roles of superoxide radical anion in signal transduction mediated by reversible regulation of protein-tyrosine phosphatase 1B. *J. Biol. Chem.* 274, 34543–34546.
- (38) Denu, J. M., and Tanner, K. G. (1998) Specific and reversible inactivation of protein tyrosine phosphatases by hydrogen peroxide: evidence for a sulfenic acid intermediate and implications for redox regulation. *Biochemistry* 37, 5633–5642.
- (39) Mahadev, K., Zilbering, A., Zhu, L., and Goldstein, B. J. (2001) Insulin-stimulated hydrogen peroxide reversibly inhibits protein-tyrosine phosphatase 1B in vivo and enhances the early insulin action cascade. *J. Biol. Chem.* 276, 21938–21942.
- (40) Tonks, N. K. (2005) Redox redux: revisiting PTPs and the control of cell signaling. *Cell* 121, 667–670.
- (41) Sivaramakrishnan, S., Keerthi, K., and Gates, K. S. (2005) A chemical model for the redox regulation of protein tyrosine phosphatase 1B (PTP1B). *J. Am. Chem. Soc.* 127, 10830–10831.
- (42) van Montfort, R. L. M., Congreve, M., Tisi, D., Carr, R., and Jhoti, H. (2003) Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1B. *Nature* 423, 773–777.
- (43) Salmeen, A., Anderson, J. N., Myers, M. P., Meng, T.-C., Hinks, J. A., Tonks, N. K., and Barford, D. (2003) Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate. *Nature* 423, 769–773.
- (44) Thornalley, P., Wolff, S., Crabbe, J., and Stern, A. (1984) The autooxidation of glyceraldehyde and other simple monosaccharides under physiological conditions catalysed by buffer ions. *Biochim. Biophys. Acta* 797, 276–287.
- (45) Halliwell, B., and Gutteridge, J. M. C. (1990) Role of free radicals and catalytic metal ions in human disease: An overview. *Methods Enzymol.* 186, 1–85.
- (46) Cox, R., Goorha, S., and Irving, C. C. (1988) Inhibition of DNA methylase activity by acrolein. *Carcinogenesis* 9, 463–465.
- (47) Vander Jagt, D. L., Hunsaker, L. A., Vander Jagt, T. J., Gomez, M. S., Gonzales, D. M., Deck, L. M., and Royer, R. E. (1997) Inactivation

- of glutathione reductase by 4-hydroxynonenal and other endogenous aldehydes. *Biochem. Pharmacol.* 53, 1133–1140.
- (48) Pocker, Y., and Janjic, N. (1988) Differential modification of specificity in carbonic anhydrase catalysis. *J. Biol. Chem.* 263, 6169–6176.
- (49) Carbone, D. L., Doorn, J. A., Kiebler, Z., and Petersen, D. R. (2005) Cysteine modification by lipid peroxidation products inhibits protein disulfide isomerase. *Chem. Res. Toxicol.* 18, 1324–1331.
- (50) Szapacs, M. E., Riggins, J. N., Zimmerman, L. J., and Liebler, D. C. (2007) Covalent adduction of human serum albumin by 4-hydroxy-2-nonenal: Kinetic analysis of competing alkylation reactions. *Biochemistry* 45, 10521–10528.
- (51) Zhang, Z.-Y. (2002) Protein tyrosine phosphatases: Structure and function, substrate specificity, and inhibitor development. *Ann. Rev. Pharmacol. Toxicol.* 42, 209–234.
- (52) Esterbauer, H., Ertl, A., and Scholz, N. (1976) The reaction of cysteine with α,β -unsaturated aldehydes. *Tetrahedron* 32, 285–289.
- (53) Hernandez-Hernandez, A., Sanchez-Yague, J., Martin-Valmaseda, E. M., and Llanillo, M. (1999) Oxidative inactivation of human and sheep platelet membrane-associated phosphotyrosine phosphatase activity. *Free Radical Biol. Med.* 26, 1218–1230.
- (54) Fu, H., Park, J., and Pei, D. (2002) Peptidyl aldehydes as reversible covalent inhibitors of protein tyrosine phosphatases. *Biochemistry* 41, 10700–10709.
- (55) Park, J., Fu, H., and Pei, D. (2003) Peptidyl aldehydes as reversible covalent inhibitors of Src homology 2 domains. *Biochemistry* 42, 5169–5167.
- (56) Hernandez-Hernandez, A., Garabatos, M. N., Rodriguez, M. C., Vidal, M. L., Lopez-Revuelta, A., Sanchez-Gallego, J. I., Llanillo, M., and Sanchez-Yague, J. (2005) Structural characteristics of a lipid peroxidation product, trans-2-nonenal, that favour inhibition of membrane-associated phosphotyrosine phosphatase activity. *Biochim. Biophys. Acta* 1726, 317–325.
- (57) Salsman, S. J., Hensley, K., and Floyd, R. A. (2005) Sensitivity of protein tyrosine phosphatase activity to the redox environment, cytochrome c, and microperoxidase. *Antioxid. Redox Signaling* 7, 1078–1088.

TX700213S